---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024430"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:58:02.891186+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q3 2022 net loss $16.2M; cash $98.7M; pipeline progress highlighted

## Summary
- Cash, cash equivalents, restricted cash equivalents and marketable securities totaled $98.7M at Sept 30, 2022, down from $117.5M at Dec 31, 2021.
- Net loss of $16.2M compared to $28.7M in Q3 2021; R&D expenses $9.1M, G&A expenses $7.2M.
- RT-102 Phase 1 Part 2 repeat-dose data expected in Q4 2022; positive Part 1 showed 300-400% greater bioavailability vs subcutaneous Forteo.
- RT-111 (ustekinumab biosimilar) preclinical development announced; Phase 1 planned in 2023.
- $30M committed loan from Avenue Venture Opportunities; up to $150M at-the-market equity offering program.

## SEC filing metadata
- accession: 0000950170-22-024430
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017022024430/0000950170-22-024430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017022024430/rani-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024430
- JSON: https://secwatch.observer/filing/0000950170-22-024430.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.